Nymox Announces Filing of Annual Report
Nymox Pharmaceutical (OTC: NYMXF) has announced the filing of its Annual Report with the Securities and Exchange Commission (SEC) on August 29, 2024. The company, which trades on the OTC Markets, made this announcement on August 30, 2024, from Irvine, California. This timely filing of the Annual Report is a important regulatory compliance step for publicly traded companies, providing investors and regulators with essential financial and operational information about the company's performance over the past year.
Nymox Pharmaceutical (OTC: NYMXF) ha annunciato il deposito del suo Rapporto Annuale presso la Securities and Exchange Commission (SEC) il 29 agosto 2024. L'azienda, che opera nei mercati OTC, ha fatto questo annuncio il 30 agosto 2024, da Irvine, California. Questo deposito tempestivo del Rapporto Annuale è un'importante misura di conformità normativa per le aziende quotate in borsa, fornendo a investitori e regolatori informazioni finanziarie e operative essenziali sulle performance dell'azienda nell'ultimo anno.
Nymox Pharmaceutical (OTC: NYMXF) ha anunciado la presentación de su Informe Anual ante la Securities and Exchange Commission (SEC) el 29 de agosto de 2024. La empresa, que cotiza en los mercados OTC, hizo este anuncio el 30 de agosto de 2024, desde Irvine, California. Esta presentación oportuna del Informe Anual es un paso importante de cumplimiento regulatorio para las compañías que cotizan en bolsa, proporcionando a los inversores y reguladores información financiera y operativa esencial sobre el rendimiento de la empresa durante el último año.
Nymox Pharmaceutical (OTC: NYMXF)는 2024년 8월 29일에 증권 거래 위원회(SEC)에 연례 보고서를 제출했다고 발표했습니다. OTC 마켓에서 거래되는 이 회사는 2024년 8월 30일 캘리포니아주 어바인에서 이 발표를 했습니다. 연례 보고서의 적시 제출은 상장 회사에 대한 중요한 규제 준수 단계로, 투자자와 규제자에게 회사의 지난 1년 동안의 성과에 대한 필수 재무 및 운영 정보를 제공합니다.
Nymox Pharmaceutical (OTC: NYMXF) a annoncé le dépôt de son Rapport Annuel auprès de la Securities and Exchange Commission (SEC) le 29 août 2024. L'entreprise, qui est cotée sur les marchés OTC, a fait cette annonce le 30 août 2024 depuis Irvine, Californie. Ce dépôt opportun du Rapport Annuel est une étape importante de conformité réglementaire pour les entreprises cotées, fournissant aux investisseurs et aux régulateurs des informations financières et opérationnelles essentielles sur la performance de l'entreprise au cours de l'année écoulée.
Nymox Pharmaceutical (OTC: NYMXF) hat die Einreichung seines Jahresberichts bei der Wertpapier- und Börsenaufsichtsbehörde (SEC) am 29. August 2024 bekannt gegeben. Das Unternehmen, das an den OTC-Märkten gehandelt wird, gab diese Ankündigung am 30. August 2024 aus Irvine, Kalifornien, bekannt. Diese fristgerechte Einreichung des Jahresberichts ist ein wichtiger regulatorischer Compliance-Schritt für börsennotierte Unternehmen und stellt Investoren sowie Regulierungsbehörden essentielle finanzielle und operative Informationen über die Unternehmensleistung im vergangenen Jahr zur Verfügung.
- Timely filing of Annual Report with SEC, demonstrating regulatory compliance
- None.
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to report that it filed its Annual Report with the Security and Exchange Commission (SEC) on August 29, 2024.
About NYMOX
Nymox is in the process of submitting, and has submitted applications for the approval to market the Company's first in class drug NYMOZARFEX™ to treat the symptoms of benign prostatic hyperplasia (BPH). BPH is one of the most common conditions affecting middle aged and elderly men throughout the world. BPH can be devastating to men who suffer from the condition. Current treatments are associated with numerous intolerable side effects including sexual problems, such as impotence and retrograde ejaculation. Medications for BPH have been associated with prostate cancer, depression, gynecomastia and other adverse effects. The majority of men stop taking the available medications due to these and other problems. Surgery is often needed for advanced BPH. Surgery is usually effective but it is not without risks, the discomforts of surgery, and BPH surgery has side effects such as permanent retrograde ejaculation for many patients.
Nymox recently reported 10-year follow-up new data on all available patients from its U.S. clinical trial of NYMOZARFEX™ for the treatment of low grade localized prostate cancer. The available long-term data newly assessed, confirmed that all available data shows that the NYMOZARFEX™ treatment had important and statistically significant benefit for reducing the long-term progression of these prostate cancers.
About NYMOZARFEX (TM) (Fexapotide)
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 NYMOZARFEX™ administrations. NYMOZARFEX™ has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.
For more information please contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of NYMOZARFEX™ to treat BPH and prostate cancer and the estimated timing of further developments for NYMOZARFEX™. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, and performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on NYMOZARFEX™, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of NYMOZARFEX™. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2023, and its Quarterly Reports.
For Further Information Contact:
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
FAQ
When did Nymox Pharmaceutical (NYMXF) file its Annual Report in 2024?
What stock exchange does Nymox Pharmaceutical (NYMXF) trade on?
Where is Nymox Pharmaceutical (NYMXF) headquartered?
